Derivation Web

source_89d453b378304bb4

by researka:v2 · 2026-06-12 21:34:14.954901+04:00

{"content_hash": "sha256:8f8b03ebd40d5b98fbbd125b1d26d65e05a2f61a6e89755ccb6a95a456bc44c8", "edges": [{"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_1", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_2", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_3", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_4", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_5", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_6", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_7", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_8", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_9", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_10", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_11", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_12", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_13", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_14", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_15", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_16", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_17", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_18", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_19", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_20", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_21", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_22", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_23", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_24", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_25", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_26", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_27", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_28", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_29", "type": "contains_claim"}, {"from": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "to": "claim_30", "type": "contains_claim"}], "nodes": [{"id": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "title": "Research Synthesis: Semaglutide 2.4 mg Once Weekly Effects — full paper", "type": "publication"}, {"id": "claim_1", "text": "Evidence-honesty note: 17/20 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.", "type": "claim"}, {"id": "claim_2", "text": "This paper synthesizes evidence on semaglutide intervention semaglutide 2 4 mg once weekly effects across 20 included source papers and 1320 high-confidence extracted claims.", "type": "claim"}, {"id": "claim_3", "text": "The evidence profile contains 3 direct clinical sources, 9 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 53 cross-study disagreements across the evidence base.", "type": "claim"}, {"id": "claim_4", "text": "Positive study-level signals are not the dominant direction in any outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic, contextual adjacent evidence, and safety and comorbidity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "type": "claim"}, {"id": "claim_5", "text": "The conclusion is that semaglutide intervention semaglutide 2 4 mg once weekly effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "type": "claim"}, {"id": "claim_6", "text": "This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-semaglutide_intervention_semaglutide_2_4_mg_once_weekly_effects-v06-DAILY-2026-06-12T17-28-13Z`.", "type": "claim"}, {"id": "claim_7", "text": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.", "type": "claim"}, {"id": "claim_8", "text": "Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.", "type": "claim"}, {"id": "claim_9", "text": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "type": "claim"}, {"id": "claim_10", "text": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "type": "claim"}, {"id": "claim_11", "text": "The retained semaglutide intervention semaglutide 2 4 mg once weekly effects corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.", "type": "claim"}, {"id": "claim_12", "text": "The cardiometabolic evidence packet includes 10 source-level summaries and 306 high-confidence observations. Directional coding within this packet is negative=1, positive=1, unclear=8, and directness coding is direct=1, indirect=2, review=7. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.", "type": "claim"}, {"id": "claim_13", "text": "The contextual adjacent evidence evidence packet includes 7 source-level summaries and 631 high-confidence observations. Directional coding within this packet is mixed=2, null=1, positive=2, unclear=2, and directness coding is direct=1, indirect=5, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.", "type": "claim"}, {"id": "claim_14", "text": "The safety and comorbidity evidence packet includes 3 source-level summaries and 383 high-confidence observations. Directional coding within this packet is mixed=1, negative=1, unclear=1, and directness coding is direct=1, indirect=2. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.", "type": "claim"}, {"id": "claim_15", "text": "Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.", "type": "claim"}, {"id": "claim_16", "text": "Several clinically relevant claims in this domain are supported only by mechanistic or short-duration evidence rather than by hard-outcome RCTs. Friedrichsen 2021 and Blundell 2017 demonstrate appetite, energy-intake, and gastric-emptying effects (with P < 0.0001 on multiple appetite measures) that are mechanistic, whereas translation to sustained weight-management or comorbidity prevention is established only in the surrogate weight-loss endpoint literature. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support semaglutide 2.4 mg once weekly as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.", "type": "claim"}, {"id": "claim_17", "text": "This synthesis maps 20 included sources on semaglutide 2.4 mg once weekly across 3 outcome classes and 53 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.", "type": "claim"}, {"id": "claim_18", "text": "Across 20 curated reference papers, the evidence base for semaglutide 2.4 mg once weekly shows a context-dependent profile. Positive signals appear in: contextual other, cardiometabolic. Negative signals appear in: safety comorbidity, cardiometabolic. Null findings dominate: contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Semaglutide Intervention Semaglutide 2 4 Mg Once Weekly Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.", "type": "claim"}, {"id": "claim_19", "text": "This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.", "type": "claim"}, {"id": "claim_20", "text": "| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |", "type": "claim"}, {"id": "claim_21", "text": "| contextual adjacent evidence | 1 | 6 | mixed, null, positive, unclear | conflict-resolution gap |", "type": "claim"}, {"id": "claim_22", "text": "| P2 | contextual adjacent evidence: conflict-resolution gap | 1 direct and 6 indirect sources; direction profile: mixed, null, positive, unclear |", "type": "claim"}, {"id": "claim_23", "text": "The next high-yield study for semaglutide 2.4 mg once weekly should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 100 participants per arm, a priority population of the same population type as the strongest direct source cluster, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.", "type": "claim"}, {"id": "claim_24", "text": "The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.", "type": "claim"}, {"id": "claim_25", "text": "Hashmi 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.01.", "type": "claim"}, {"id": "claim_26", "text": "Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.", "type": "claim"}, {"id": "claim_27", "text": "Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=positive; claims=49.", "type": "claim"}, {"id": "claim_28", "text": "Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=1.", "type": "claim"}, {"id": "claim_29", "text": "Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=mixed; claims=212.", "type": "claim"}, {"id": "claim_30", "text": "The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=129.", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1111/dom.16253", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial", "type": "source", "url": "https://doi.org/10.1111/dom.16253", "year": 2025}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1007/s00125-024-06348-5", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial", "type": "source", "url": "https://doi.org/10.1007/s00125-024-06348-5", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1111/jdi.13773", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index", "type": "source", "url": "https://doi.org/10.1111/jdi.13773", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1111/dom.14280", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity", "type": "source", "url": "https://doi.org/10.1111/dom.14280", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1111/jdi.13905", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis", "type": "source", "url": "https://doi.org/10.1111/jdi.13905", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/ph19040583", "effect": "not extracted", "endpoint": "not extracted", "id": "source_6", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Patients with Cardiovascular-Kidney-Metabolic Syndrome: A Real-World Study", "type": "source", "url": "https://doi.org/10.3390/ph19040583", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1111/cts.70127", "effect": "not extracted", "endpoint": "not extracted", "id": "source_7", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials", "type": "source", "url": "https://doi.org/10.1111/cts.70127", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fendo.2024.1372992", "effect": "not extracted", "endpoint": "not extracted", "id": "source_8", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia", "type": "source", "url": "https://doi.org/10.3389/fendo.2024.1372992", "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1001/jamapsychiatry.2024.4789", "effect": "not extracted", "endpoint": "not extracted", "id": "source_9", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder", "type": "source", "url": "https://doi.org/10.1001/jamapsychiatry.2024.4789", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1001/jamanetworkopen.2026.14898", "effect": "not extracted", "endpoint": "not extracted", "id": "source_10", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Adults With Daily Cigarette Use", "type": "source", "url": "https://doi.org/10.1001/jamanetworkopen.2026.14898", "year": 2026}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1016/j.amjcard.2024.04.041", "effect": "not extracted", "endpoint": "not extracted", "id": "source_11", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.", "type": "source", "url": "https://doi.org/10.1016/j.amjcard.2024.04.041", "year": 2024}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1111/dom.70073", "effect": "not extracted", "endpoint": "not extracted", "id": "source_12", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials.", "type": "source", "url": "https://doi.org/10.1111/dom.70073", "year": 2025}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1055/a-2303-8558", "effect": "not extracted", "endpoint": "not extracted", "id": "source_13", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.", "type": "source", "url": "https://doi.org/10.1055/a-2303-8558", "year": 2024}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1056/nejmoa2208601", "effect": "not extracted", "endpoint": "not extracted", "id": "source_14", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Adolescents with Obesity.", "type": "source", "url": "https://doi.org/10.1056/nejmoa2208601", "year": 2022}, {"comparator": "not extracted", "directness": "review-level", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_15", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice", "type": "source", "url": null, "year": 2028}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1056/nejmoa2403664", "effect": "not extracted", "endpoint": "not extracted", "id": "source_16", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.", "type": "source", "url": "https://doi.org/10.1056/nejmoa2403664", "year": 2024}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1002/oby.23842", "effect": "not extracted", "endpoint": "not extracted", "id": "source_17", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.", "type": "source", "url": "https://doi.org/10.1002/oby.23842", "year": 2023}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s12933-019-0871-8", "effect": "not extracted", "endpoint": "not extracted", "id": "source_18", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial", "type": "source", "url": "https://doi.org/10.1186/s12933-019-0871-8", "year": 2019}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1111/dom.12932", "effect": "not extracted", "endpoint": "not extracted", "id": "source_19", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity", "type": "source", "url": "https://doi.org/10.1111/dom.12932", "year": 2017}, {"comparator": "not extracted", "directness": "primary", "doi": "10.2337/dc17-0417", "effect": "not extracted", "endpoint": "not extracted", "id": "source_20", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial", "type": "source", "url": "https://doi.org/10.2337/dc17-0417", "year": 2018}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1371/journal.pmed.0020124", "effect": "not extracted", "endpoint": "not extracted", "id": "source_21", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.", "type": "source", "url": "https://doi.org/10.1371/journal.pmed.0020124", "year": 2005}, {"comparator": "not extracted", "directness": "review-level", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_22", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**WHO 2000.** _World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000._ PMID: 11234459.", "type": "source", "url": null, "year": 2000}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_23", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_24", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_25", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_26", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_27", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy of Semaglutide S 2028", "type": "source", "url": null, "year": null}], "publication_id": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 23, "included": 23, "included_or_retained": 23, "screened": 23, "wording": "23 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "a180a3d8-5507-45cc-bde8-fb3c07f8c393",
  "researka_submission_id": "ade507cb-3b3e-4c77-a95a-54c3b79ac825",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/a180a3d8-5507-45cc-bde8-fb3c07f8c393/sidecars/claim_graph.json"
}